Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.
The relationship between nevirapine plasma concentrations and the durability of both viral suppression (VS) and selection of nevirapine primary resistance mutations (PRMs) was evaluated. A nevirapine trough concentration (Ctrough) of >4,300 ng/ml was found to predict longer VS. Patients with nevirapine Ctrough s ranging from 3,100 to 4,300 ng/ml had higher probabilities of developing PRMs than those with nevirapine Ctrough s below and above this concentration interval.
González de Requena
D
D
Department of Infectious Diseases, University of Turin, Italy.
Bonora
S
S
Garazzino
S
S
Sciandra
M
M
D'Avolio
A
A
Raiteri
R
R
Marrone
R
R
Boffito
M
M
De Rosa
F G
FG
Sinicco
A
A
Di Perri
G
G
D000328:Adult; D019380:Anti-HIV Agents / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008297:Male; D009154:Mutation; D019829:Nevirapine / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D012372:ROC Curve; D012189:Retrospective Studies
D019380:Anti-HIV Agents; D019829:Nevirapine